Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.

MLA

Camisaschi, Chiara, et al. “Immune Landscape and in Vivo Immunogenicity of NY-ESO-1 Tumor Antigen in Advanced Neuroblastoma Patients.” BMC Cancer, vol. 18, no. 1, Oct. 2018, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12885-018-4910-8.

APA

Camisaschi, C., Renne, S. L., Beretta, V., Rini, F., Spagnuolo, R. D., Tuccitto, A., Podda, M. G., Parmiani, G., Rivoltini, L., Collini, P., Castelli, C., & Luksch, R. (2018). Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients. BMC Cancer, 18(1), 1–11. https://doi.org/10.1186/s12885-018-4910-8

Chicago

Camisaschi, Chiara, Salvatore Lorenzo Renne, Valeria Beretta, Francesca Rini, Rosalin Dolores Spagnuolo, Alessandra Tuccitto, Marta Giorgia Podda, et al. 2018. “Immune Landscape and in Vivo Immunogenicity of NY-ESO-1 Tumor Antigen in Advanced Neuroblastoma Patients.” BMC Cancer 18 (1): 1–11. doi:10.1186/s12885-018-4910-8.